MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dysarthria"

  • 2025 International Congress

    Exploring the Trade-offs Between Speech and Gait in Parkinson’s Disease

    YF. Chiu, J. Longhurst, A. Fletcher, T. Loux (Saint Louis, USA)

    Objective: The goal of the study was to explore speech and gait performance trade-off when individuals with Parkinson’s disease (PD) engaged in concurrent speaking and…
  • 2025 International Congress

    Assessment of Hypomimia in Parkinson’s Disease

    T. Grover, T. Foltynie, J. Candelario, C. Milabo, C. Girges, M. Salazar, J. Esperida, P. Limousin (London, United Kingdom)

    Objective: To compare spontaneous facial expression of Happiness as measured by Action Units; AU6 (cheek raise) and AU12 (smile) between individuals with Parkinson’s Disease (PD)…
  • 2024 International Congress

    Speech Biomarkers for Dysarthria in Parkinson’s Disease — Clinical Validation Across two Languages

    J. Tröger, E. Baykara, F. Dörr, J. Rusz, J R. Orozco-Arroyave (Saarbrücken, Germany)

    Objective: To identify reliable speech biomarkers for assessing dysarthria in individuals with Parkinson's disease (PD) and ensuring their clinical validity across languages. Background: This study…
  • 2024 International Congress

    Alpha-synuclein aggregate pathology in the cranial sensorimotor system in a mouse model of Parkinson’s disease.

    A. Schaser (West Lafayette, USA)

    Objective: The goal of this study was to examine the effect of a potential underlying mechanism responsible for the complex voice deficits that exist in…
  • 2024 International Congress

    Dandy-Walker syndrome. A case study.

    GM. Mussagaliyeva (Almaty, Kazakhstan)

    Objective: Present a case study with rare congenital disease for further сreating a database and developing algorithms for the management of such cases in the…
  • 2024 International Congress

    Passive smartphone speech monitoring in isolated rapid eye movement sleep behaviour disorder

    V. Illner, M. Novotny, T. Kouba, T. Tykalova, M. Simek, P. Sovka, J. Svihlik, E. Ruzicka, K. Sonka, P. Dusek, J. Rusz (Prague 6, Czech Republic)

    Objective: We aimed to design and test the sensitivity of a fully-automated and noise-resistant smartphone-based system that can unobtrusively screen for prodromal parkinsonian speech disorder…
  • 2024 International Congress

    Effects on Speech After the Use of Swallow Against Resistance Exercise Device in Parkinson’s Disease Patients

    R. Lee, H. Hassan, E. Jackowiak, R. Brennan, M. Kern, R. Shaker (Milwaukee, USA)

    Objective: To evaluate the effect on speech after a strength training exercise targeting the swallowing biomechanics in Parkinson’s disease (PD) patients. Background: Dysarthria and dysphagia…
  • 2024 International Congress

    Examining the Effects of Deep Brain Stimulation on Speech in Parkinson’s Disease

    H. Kabakoff, A. Mogilner, M. Pourfar, A. Flinker (Brooklyn, USA)

    Objective: The current goal is to use pilot data to explain speech changes in patients with Parkinson’s disease (PD) who have Deep Brain Stimulation (DBS)…
  • 2024 International Congress

    Detecting impulsivity through speech in patients with Parkinson’s Disease: A principle proof study

    T. Thies, E. Mallick, S. Jost, J. Tröger, M. Barbe (Cologne, Germany)

    Objective: To identify speech biomarkers to assess impulsivity in patients with Parkinson's disease (PwPD). Background: Although PD mainly presents with motor symptoms, the burden of…
  • 2024 International Congress

    Craniofacial Myoclonus: A Disabling Complication of Amantadine Therapy

    S. Bhushan, Mph, S. Brillman, Md (Palo Alto, USA)

    Objective: We describe a patient who developed amantadine-induced craniofacial myoclonus with speech impairment. Few cases have been reported [1], thus we offer an additional case…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 16
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley